JP2022520083A - Jak2阻害剤の結晶形態 - Google Patents

Jak2阻害剤の結晶形態 Download PDF

Info

Publication number
JP2022520083A
JP2022520083A JP2021547092A JP2021547092A JP2022520083A JP 2022520083 A JP2022520083 A JP 2022520083A JP 2021547092 A JP2021547092 A JP 2021547092A JP 2021547092 A JP2021547092 A JP 2021547092A JP 2022520083 A JP2022520083 A JP 2022520083A
Authority
JP
Japan
Prior art keywords
crystalline
compound
solvate
powder diffraction
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021547092A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022520083A5 (cg-RX-API-DMAC7.html
Inventor
ロベール,ブノワ
ビヨー,パスカル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Impact Biomedicines Inc
Original Assignee
Impact Biomedicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Impact Biomedicines Inc filed Critical Impact Biomedicines Inc
Publication of JP2022520083A publication Critical patent/JP2022520083A/ja
Publication of JP2022520083A5 publication Critical patent/JP2022520083A5/ja
Priority to JP2024212168A priority Critical patent/JP2025032217A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021547092A 2019-02-12 2020-02-11 Jak2阻害剤の結晶形態 Pending JP2022520083A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024212168A JP2025032217A (ja) 2019-02-12 2024-12-05 Jak2阻害剤の結晶形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1902018 2019-02-12
FR1902018A FR3092581A1 (fr) 2019-02-12 2019-02-12 Formes cristallines d'un inhibiteur de jak2
PCT/US2020/017764 WO2020167844A1 (en) 2019-02-12 2020-02-11 Crystalline forms of a jak2 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024212168A Division JP2025032217A (ja) 2019-02-12 2024-12-05 Jak2阻害剤の結晶形態

Publications (2)

Publication Number Publication Date
JP2022520083A true JP2022520083A (ja) 2022-03-28
JP2022520083A5 JP2022520083A5 (cg-RX-API-DMAC7.html) 2023-02-20

Family

ID=68281482

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021547092A Pending JP2022520083A (ja) 2019-02-12 2020-02-11 Jak2阻害剤の結晶形態
JP2024212168A Pending JP2025032217A (ja) 2019-02-12 2024-12-05 Jak2阻害剤の結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024212168A Pending JP2025032217A (ja) 2019-02-12 2024-12-05 Jak2阻害剤の結晶形態

Country Status (13)

Country Link
US (1) US20220332706A1 (cg-RX-API-DMAC7.html)
EP (1) EP3927704A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022520083A (cg-RX-API-DMAC7.html)
KR (1) KR20210148110A (cg-RX-API-DMAC7.html)
CN (1) CN114026088A (cg-RX-API-DMAC7.html)
AU (1) AU2020221796A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021015318A2 (cg-RX-API-DMAC7.html)
EA (1) EA202192237A1 (cg-RX-API-DMAC7.html)
FR (1) FR3092581A1 (cg-RX-API-DMAC7.html)
IL (1) IL285427A (cg-RX-API-DMAC7.html)
MX (1) MX2021009423A (cg-RX-API-DMAC7.html)
SG (1) SG11202108607QA (cg-RX-API-DMAC7.html)
WO (1) WO2020167844A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY209349A (en) 2018-09-25 2025-07-03 Impact Biomedicines Inc Methods of treating myeloproliferative disorders
US12559463B2 (en) 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009513703A (ja) * 2005-11-01 2009-04-02 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
WO2013013195A1 (en) * 2011-07-21 2013-01-24 Sanofi Compositions and methods for treating polycythemia vera and essential thrombocythemia
JP2013541595A (ja) * 2010-11-07 2013-11-14 ターゲジェン インコーポレーティッド 骨髄線維症を処置するための組成物及び方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020504711A (ja) * 2016-12-21 2020-02-13 バイオセリックス, インコーポレイテッド タンパク質を標的とすることにおいて使用するための、チエノピロール誘導体、その組成物、方法、および使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009513703A (ja) * 2005-11-01 2009-04-02 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
JP2013541595A (ja) * 2010-11-07 2013-11-14 ターゲジェン インコーポレーティッド 骨髄線維症を処置するための組成物及び方法
WO2013013195A1 (en) * 2011-07-21 2013-01-24 Sanofi Compositions and methods for treating polycythemia vera and essential thrombocythemia

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PHARM TECH JAPAN, vol. 18, no. 10, JPN7014002019, 2002, pages 81 - 96, ISSN: 0005570793 *
芦澤一英, 医薬品の多形現象と晶析の化学, JPN6015027444, 2002, pages 273 - 278, ISSN: 0005570794 *
高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0005570795 *

Also Published As

Publication number Publication date
MX2021009423A (es) 2021-11-17
EP3927704A1 (en) 2021-12-29
SG11202108607QA (en) 2021-09-29
AU2020221796A1 (en) 2021-08-12
US20220332706A1 (en) 2022-10-20
FR3092581A1 (fr) 2020-08-14
KR20210148110A (ko) 2021-12-07
BR112021015318A2 (pt) 2021-10-05
WO2020167844A1 (en) 2020-08-20
IL285427A (en) 2021-09-30
EA202192237A1 (ru) 2021-12-14
EP3927704A4 (en) 2022-12-28
CN114026088A (zh) 2022-02-08
JP2025032217A (ja) 2025-03-11

Similar Documents

Publication Publication Date Title
RU2733412C2 (ru) Поликристаллическая форма свободного основания или соли присоединения кислоты ингибитора egfr, способ её получения и применение
ES2623608T5 (es) Forma cristalina de 4-metil-N-[3-(4-metil-imidazol-1-il)-5-trifluoro-metil-fenil]-3-(4-piridin-3-il-pirimidin-2-il-amino)-benzamida
TW202408510A (zh) Cdk抑制劑及其磷酸鹽的多晶型、其製備方法、包含其的醫藥組合物及其用途
EP3176173A1 (en) Crystalline free bases of c-met inhibitor or crystalline acid salts thereof, and preparation methods and uses thereof
US10150770B2 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
JP2025032217A (ja) Jak2阻害剤の結晶形態
JP2022519885A (ja) Jak2阻害剤の結晶形態
AU2017373784B2 (en) Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists
WO2018006870A1 (zh) Galunisertib的晶型及其制备方法和用途
JP2023536892A (ja) Jak阻害剤化合物及びその使用
TW202317098A (zh) 一種egfr抑制劑的多晶型
CN115572298A (zh) 一种核苷类似物及其盐的晶型、制备方法和应用
JP2025503010A (ja) キナーゼ阻害剤の塩結晶形及び遊離塩基結晶形
WO2021073494A1 (en) The salts of a compound and the crystalline forms thereof
US20100179162A1 (en) Crystal forms of 4-[6-methoxy-7(3-piperidin-1-yl-propoxy) quinazoline-4yl) piperazine-1-carboxylic acid (4-isopropoxyphenyl)-amide
AU2023412228A1 (en) Crystal form of fluorine-substituted indazole compound and use thereof
TW202506661A (zh) 一種酪氨酸激酶抑制劑的可藥用鹽、結晶形式及其製備方法
CN103864763B (zh) 3-(5-(4-(3-氟丙基)哌嗪-1-基)苯并咪唑-2-基)-1-氮杂薁-2-酮的单水合晶型及其制备方法与药物组合物
CN112851643A (zh) 嘧啶苯甲酰胺化合物的盐酸盐及其用途

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230210

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240510

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241205

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20260619

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260630